Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency (EMA) for approval for people with BRAF V600 mutation-positive metastatic melanoma.

GlaxoSmithKline (GSK), The University of Manchester, and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research (MCCIR), a unique collaboration to establish a world-leading translational centre for inflammatory diseases.

Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis.

AstraZeneca announced new health economics data from a substudy of the PLATO trial showed that treating a broad spectrum of acute coronary syndrome (ACS) patients with BRILIQUE (ticagrelor) was more cost-effective than treatment with generic clopidogrel.

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Medicines for Malaria Venture (MMV) have signed an alliance agreement to research malaria treatments as well as the first research project agreement within the framework of the alliance.

Novartis announced that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease[4].

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.(1)